Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Share this content:

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Pfizer
GlaxoSmithKline

Contact
Maryellen Sun, MD
617-754-2559
msun@bidmc.harvard.edu

Principal Investigator
Maryellen Sun, MD, Beth Israel Deaconess Medical Center

ClinicalTrials.gov Identifier
NCT00749320

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters